Pharmaceutical companies have clearly recognized the importance of defining the API phase early in the drug development process to ensure late stage development success. They also have incorporated the preformulation workflow early in the lead optimization process to assess the formulation risks of a compound. This new approach significantly speeds up the drug development process and increases efficiency. Our workflows integrate drug discovery and development paradigms to provide you with key information using small amounts of your compound to help you make “go/no go” decisions early in drug development.
Physicochemical characterization is essential for a fundamental understanding of your API and critical to the drug development process. Every regulatory agency requires a certain level of characterization before any clinical trial can be performed. >>
Solubility Enhancement and Early Formulation Development
We work with our scientific advisory board to establish vehicle platforms and workflows that accurately assess compound solubility (kinetic and equilibrium) and stability so that the proper vehicle >>
Early Solid Form Screening and Selection
We understand that different screenings should be applied to different situations and we work with you to choose the best screening based on the issues with your compound. We will clearly provide options and risk >>
Understanding the physicochemical risks associated with your compound are paramount to successful formulation development. Crystal Pharmatech will systematically evaluate your compound and clearly map out >>